Emerging World Pharma Stock Net Income
| EWPI Stock | USD 0.0001 0.00 0.00% |
By evaluating key metrics such as revenue growth, profitability, cash flow trends, and balance sheet strength, investors can better assess Emerging World's long-term financial health and intrinsic value.
| Last Reported | Projected for Next Year | ||
| Net Loss | -369.3 K | -350.8 K | |
| Net Loss | -369.3 K | -350.8 K | |
| Net Loss | -369.3 K | -350.8 K |
Emerging | Net Income | Build AI portfolio with Emerging Stock |
Emerging World Pharma Company Net Income Analysis
Emerging World's Net income is the profit of a company for the reporting period, which is derived after taking revenues and gains and subtracting all expenses and losses. Net income is one of the most-watched numbers by money managers as well as individual investors.
Current Emerging World Net Income | (410.32 K) |
Most of Emerging World's fundamental indicators, such as Net Income, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Emerging World Pharma is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
Emerging Operating Income
Operating Income |
|
Based on the recorded statements, Emerging World Pharma reported net income of (410,316). This is 100.12% lower than that of the Healthcare sector and 99.89% lower than that of the Drug Manufacturers - Specialty & Generic industry. The net income for all United States stocks is 100.07% higher than that of the company.
Emerging Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Emerging World's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Emerging World could also be used in its relative valuation, which is a method of valuing Emerging World by comparing valuation metrics of similar companies.Emerging World is currently under evaluation in net income category among its peers.
Emerging Fundamentals
| Current Valuation | 2.15 M | ||||
| Shares Outstanding | 119.3 M | ||||
| Net Income | (410.32 K) | ||||
| Cash And Equivalents | 118.42 K | ||||
| Total Debt | 3.2 M | ||||
| Current Ratio | 0.05 X | ||||
| Book Value Per Share | (0.01) X | ||||
| Cash Flow From Operations | (138.59 K) | ||||
| Earnings Per Share | (0) X | ||||
| Beta | 502.74 | ||||
| Market Capitalization | 11.9 K | ||||
| Total Asset | 2.71 M | ||||
| Retained Earnings | (1.71 M) | ||||
| Working Capital | (4.07 M) | ||||
| Current Liabilities | 4.07 M | ||||
| Net Asset | 2.71 M |
About Emerging World Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Emerging World Pharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Emerging World using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Emerging World Pharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| DD | Dupont De Nemours | |
| CRDO | Credo Technology Group | |
| GOOG | Alphabet Inc Class C | |
| BAC | Bank of America | |
| CRM | Salesforce |
Check out Emerging World Piotroski F Score and Emerging World Altman Z Score analysis. You can also try the Odds Of Bankruptcy module to get analysis of equity chance of financial distress in the next 2 years.
Is Drug Manufacturers - Specialty & Generic space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Emerging World. If investors know Emerging will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Emerging World listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0) |
The market value of Emerging World Pharma is measured differently than its book value, which is the value of Emerging that is recorded on the company's balance sheet. Investors also form their own opinion of Emerging World's value that differs from its market value or its book value, called intrinsic value, which is Emerging World's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Emerging World's market value can be influenced by many factors that don't directly affect Emerging World's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Emerging World's value and its price as these two are different measures arrived at by different means. Investors typically determine if Emerging World is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Emerging World's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.